Effects of Vitamin D Supplementation on Body Composition and Metabolic Risk Factors in Men: A Randomized Controlled Trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Vitamin D might play a role in metabolic processes and obesity.

The researchers therefore examined vitamin D effects on metabolic markers and obesity in a randomized controlled trial (RCT).

Who Took Part

According to the abstract, 200 men were involved.

PubMed indexes the participants as teenagers, young adults, adults, middle-aged adults and older adults, men only.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

What Was Measured

Outcome measures were metabolic markers, anthropometric measures, and body composition assessed by Dual-energy X-ray absorptiometry.

The subject headings attached to it are Adiposity, Age Factors, Austria, Biomarkers, Blood Glucose, Cholecalciferol and Dietary Supplements.

The authors tagged it with the keywords body composition, insulin sensitivity, obesity, randomized controlled trial and vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 200 men.

The publication is from 2019 (Nutrients), a journal based in Switzerland.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.